Beta Amyloid Inhibitors
Beta amyloid inhibitors are compounds designed to prevent the aggregation and accumulation of beta amyloid peptides in the brain, particularly in the context of Alzheimer's disease (AD). Beta amyloid peptides are fragments of amyloid precursor protein (APP) that can aggregate to form insoluble plaques, which are a hallmark pathology of AD. These inhibitors target various stages of beta amyloid production and aggregation, including inhibiting enzymes involved in beta amyloid synthesis, promoting beta amyloid clearance, or preventing its aggregation into toxic oligomers and fibrils. By reducing beta amyloid accumulation and toxicity, these inhibitors aim to slow down or halt the progression of AD pathology, potentially preserving cognitive function and neuronal health.
- Structure
- Product name
- CAS No.
- Molecular formula
- Inquiry
Total:1 Page 1 of 1 1